$690 Million



Bookrunner, November 2021

1.50% Senior Convertible Notes

Amyris (NASDAQ:AMRS) is a synthetic biotechnology company and a supplier of substantiable and natural ingredients. The Company engineers microbes and uses them as catalysts to metabolize renewable, plant-sourced sugars into high-value ingredients that are manufactured at industrial scale. The Company has its own family of consumer brands and a partnership model where revenue is generated from the sale of molecules to partners and royalty revenue is earned from the partners’ sales of products to their customers. 

More Like This

May 2022
$82 Million

Series C Convertible Preferred

Exclusive Placement Agent

View Details >
Sep 2021
$747.5 Million

1.25% Senior Convertible Notes


View Details >
Aug 2021
$316.25 Million
Alphatec Holdings

0.75% Senior Convertible Notes Offering


View Details >